Research-Driven Pharmas Could Diverge into 2 Groups Based on Dependence on Off-Patent Drugs: FPMAJ Chair

FPMAJ Chairman Masafumi Nogimori A series of recent government policies will reshape Japan’s pharmaceutical landscape by compelling research-oriented companies to split into two groups - one focusing on innovative medicines and the other on generics and long-listed products - a...read more